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Background 
Cystic Fibrosis (CF) is a genetic condition affecting 1 in 2,500 people. CF is an 
autosomal recessive disorder, caused by a mutation in the gene coding for the 
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR). CFTR is a chloride 
channel, which is found in many body systems including the respiratory tract, the gut 
and reproductive system. In the apical membrane of respiratory epithelial cells, 
CFTR function is essential to ensure that cilia lining the respiratory tract are bathed 
in an aqueous layer. This layer enables cilia to beat in a coordinated fashion, 
propelling mucus, particulate matter and micro-organisms up the respiratory tract. 
Lack of CFTR function leads failure of mucociliary clearance and accumulation of 
mucus and micro-organisms in the respiratory tract. This in turn leads to infection, 
inflammation and bronchiectasis. (1)  
 
Rationale  
CF predominantly affects the lungs; however, the multi-organ disease process can 
result in CF related diabetes, liver disease, infertility and digestive disruption. (2) Due 
to the high burden of disease on many organs and the increasing life expectancy, 
the average CF patient is on eight or more medications daily. (3) The complex 
treatment regimen in CF patients can include time consuming treatments for 
example airway clearance techniques, inhaled antibiotics, and enzyme replacements 
resulting in treatment regimens necessitating on average 137 minutes per child or 
150 minutes for an adult every day. (2) (4)  
 
The James Lind Alliance Priority Setting Partnership in Cystic Fibrosis explored the 
research priorities of the CF community in order to produce a “top 10” list of priorities 
for clinical research in CF. The first priority was investigating ways to reduce 
treatment burden. (5) High treatment burden is well recognised within the CF 
community and is associated with a poorer quality of life. (6) Reduced compliance 
and subsequent wasted medication, and a potential deterioration in health are 
consequences of high treatment burden. (7)  
 
‘Treatment burden’ is non-specific terminology used to describe the increased work 
load associated with health care consequently affecting an individual’s physical and 
psychological wellbeing. (8) Aspects of treatment burden can include the volume of 
medication, time taken to administer medications, or how patients access their 
prescriptions or medications. Furthermore, access to medications is documented to 
be a problem for patients with a variety of chronic diseases. (9) (10) Common 
difficulties include pharmacy stock, medication errors and short durations of 
prescriptions. (9) (10) (11)  
 
We propose a qualitative observational study to explore how patients with CF access 
their medications to examine obstacles contributing to their treatment burden and 
explore potential solutions. We will investigate whether barriers are similar to the 
non-CF community. The data will be assessed alongside the views and perceptions 
of both general practitioners (GPs) and community pharmacists.  
 
Objectives  
1. Review the current system for accessing medications in Primary Care. 
2. Explore the difficulties patients with CF experience when accessing their 
medications in primary care. 
3. Review the perception of general practitioners when prescribing medications 
for patients with CF. 
4. Review the perceptions of community pharmacists when reviewing and 
dispensing medications for patients with CF. 
 
Outcome  
1. To better understand the number one research priority of reducing treatment 
burden for a patient with CF. 
2. To document the barriers to accessing medications for patients with CF and 
generate potential solutions. 
3. To represent the views of pharmacists and general practitioners when 
prescribing, reviewing and dispensing medications for patients with CF.  
 
Study Design  
The James Lind CF2 launched a SurveyMonkey questionnaire in March 2018 
focussing on how to simplify treatment burden for patients with CF.  A wealth of 
qualitative and quantitative data were collected from the CF community on treatment 
burden including their problems of accessing medications. The data relating to 
accessing medication will be analysed prior to completing the GP and community 
pharmacists survey.  
 
A SurveyMonkey questionnaire will be developed for both GPs and community 
pharmacists. The questionnaire for the GPs and pharmacists will be developed with 
the analysed James Lind CF2 data and guidance of both professions within a small 
focus group. A mixture of both qualitative, ‘free text’ and quantitative ‘single answer’ 
questions will be incorporated. The questionnaires will be available for 4 weeks from 
June 2019 or until 100 participants have completed the study.  
Ethics approval 
Faculty of Medicine & Health Sciences Research Ethics Committee deemed this 
work not to require ethical approval on 30/4/2019. 
Consent  
A privacy policy will be made available within the survey. The questionnaire is 
anonymous, and no personal data will be stored or financial incentive given to 
complete the questionnaire. Completing the questionnaire is optional and can be 
terminated at any point.  
 
Recruitment  
Questionnaire participants will be invited to take part in the study on social media, 
including Twitter and Facebook platforms. The link will be tweeted from the 
@questioncf account and groups on Facebook such as Women in  
Pharmacy, NASGP group will be invited to complete the questionnaire. The Royal 
college of Pharmacists and Royal College of GPs will be contacted to advertise the 
questionnaire.   
 
Inclusion and exclusion criteria 
Inclusion criteria for questionnaire specific to that population group:  
- GP  
- Community Pharmacist  
- Not restricted by country 
 
Exclusion criteria:  
- Any healthcare professional that is not a GP or Community pharmacist  
 
Data management and analysis  
The survey data will be downloaded from Surveymonkey into Excel for quantitative 
analysis and then into NVivo for qualitative analysis.  
 
Quantitative analysis 
We will use Excel to present frequency data for the closed questions in the survey to 




Free text responses will be analysed in NVivo to identify themes across the data. We 
will describe the data using word frequencies, word clouds and free text quotes to 
support our findings. 
 
Comparative analysis 
Data from the patient survey previously collected as part of the James Lind CF2 
work will be used to compare with views of the GP and community pharmacist 




Proposed timeline is to launch the questionnaire in June 2019 with analysis of the 
data to be conducted in July 2019. 
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